The role of sympathetic nervous system in the progression of chronic kidney disease in the era of catheter based sympathetic renal denervation

Current Clinical Pharmacology

Volumn 8, Issue 3, 2013, Pages 197-205

  Petras, Dimitrios ^a   Koutroutsos, Konstantinos ^b   Kordalis, Athanasios ^c   Tsioufis, Costas ^c   Stefanadis, Christodoulos ^c  

^a HIPPOKRATION HOSPITAL   (Greece)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Chronic kidney disease renal ablation; Resistant hypertension

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALISKIREN; ALPHA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; EPROSARTAN; LOSARTAN; MOXONIDINE; NITRIC OXIDE; OXIDOREDUCTASE; PRAZOSIN; RENALASE; RENIN INHIBITOR; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DISEASE COURSE; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; HUMAN; HYPERTENSION; KIDNEY DENERVATION; KIDNEY FUNCTION; KIDNEY INJURY; MUSCLE SYMPATHETIC NERVE ACTIVITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; RESISTANT HYPERTENSION; REVIEW; SODIUM ABSORPTION; SYMPATHETIC HYPERACTIVITY; SYMPATHETIC INNERVATION; SYMPATHETIC TONE; VASOCONSTRICTION;

ANIMALS; CATHETER ABLATION; DISEASE PROGRESSION; HUMANS; KIDNEY; NITRIC OXIDE; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM;

EID: 84882779717     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/15748847113089990047     Document Type: Review

References (114)

1. Klein IH, Ligtenberg G, Neumann J, et al. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol 2003; 14: 3239-44.
2. Vink EE, Blankestijn PJ. Evidence and consequences of the central role of the kidneys in the pathophysiology of sympathetic hyperactivity. Front Physiol 2012; 3: 29.
3. DiBona GF. The sympathetic nervous system and hypertension: recent developments. Hypertension 2004; 43: 147-50.
4. Kopp UC, DiBona GF. The neural control of renal function. In: Seldin G, Giebisch G, Eds. The Kidney: Physiology and Pathophysiology. 3rd ed. New York: Raven 2006; pp. 981-1006
5. Barajas L, Powers K, Wang P. Innervation of the renal cortical tubules: a quantitative study. Am J Physiol 1984; 247: 50-60
6. Esler M, Rumantir M, Kaye D, et al. Sympathetic nerve biology in essential hypertension. Clin Exp Pharmacol Physiol 2001; 28: 986-9.
7. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997; 77: 175-97.
8. DiBona G.F.(2000b).Neural control of the kidney: functionally specific renal sympathetic nerve fibers. Am J Physiol Regul Integr Comp Physiol 2000; 279: 1517-24.
9. Osborn JL, DiBona GF, Thames MD. Beta-1 receptor mediation of renin secretion elicited by low-frequency renal nerve stimulation. J Pharmacol Exp Ther 1981; 216: 265-9.
10. Johns EJ. Role of angiotensin II and the sympathetic nervous system in the control of renal function. J Hypertens 1989; 7: 695-701.
11. Jackson EK. Autonomic control of the kidney. In: Robertson D, Biaggioni I, Burnstock G, Low P, Eds. Primer on the Autonomic Nervous System. 2nd ed. New York: Elsevier, 2004; pp. 157-61.
12. Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol 1992; 262: 763-78.
13. Hesse IF, Johns EJ. The effect of graded renal nerve stimulation on renal function in the anaesthetized rabbit. Comp Biochem Physiol A Comp Physiol 1984; 79: 409-14.
14. Johns EJ, Manitius J. An investigation into the neural regulation of calcium excretion by the rat kidney. J Physiol 1987; 383: 745-55.
15. DiBona GF, Sawin LL. Effect of renal nerve stimulation on NaCl and H2O transport in Henle's loop of the rat. Am J Physiol 1982; 243: 576-80.
16. Yoshimoto M, Sakagami T, Nagura S, et al. Relationship between renal sympathetic nerve activity and renal blood flow during natural behavior in rats. Am J Physiol Regul Integr Comp Physiol 2004; 286: 881-7.
17. Malpas SC, Evans RG. Do different levels and patterns of sympathetic activation all provoke renal vasoconstriction? J Auton Nerv Syst 1998; 69: 72-82
18. Tsioufis C, Papademetriou V, Dimitriadis K, et al. Chronic effects of percutaneous renal sympathetic denervation on renal hemodynamics and plasma norepinephrine levels using a novel catheter for radiofrequency ablation. In: ACC 2012, March 24-27, 2012, Chicago, IL, USA. Presentation Number: 926-8.
19. Wu W, Scholey JW, Sonnenberg H, Melo LG. Renal vascular morphology and haemodynamics in Dahl salt-sensitive rats on high salt low potassium diet: neural and genetic influences. J Hypertens 2000; 18: 783-93.
20. Stella A, Zanchetti A. Functional role of renal afferents. Physiol Rev 1991; 71: 659-82.
21. Ciriello J. Afferent renal inputs to paraventricular nucleus vasopressin and oxytocin neurosecretory neurons. Am J Physiol 1998; 275: 1745-54.
22. Coote JH. A role for the paraventricular nucleus of the hypothalamus in the autonomic control of heart and kidney. Exp Physiol 2004; 90: 169-73.
23. Blankestijn PJ, Ligtenberg G, Klein IH, et al. Sympathetic overactivity in renal failure controlled by ACE inhibition: clinical significance. Nephrol Dial Transplant 2000; 15: 755-58.
24. Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease. Nephrol Dial Transplant 2004; 19: 1354-7.
25. Joles JA and Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004; 43: 699-706.
26. Koomans HA, Blankestijn PJ and Joles JA. Sympathetic hyperactivity in chronic renal failure: a wake-upcall. J Am Soc Nephrol 2004; 15: 524-537.
27. Neumann J, Ligtenberg G, Klein II, et al. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance and treatment. Kidney Int 2004; 65: 1568-76.
28. Siddiqi L, Joles JA, Grassi G, et al. Is kidney ischemia the central mechanism in parallel activation of the rennin and sympathetic system? J Hypertens 2009; 27: 1341-9.
29. Katholi RE, Winternitz SR, Oparil S: Decrease in peripheral sympathetic nervous system activity following renal denervation or unclipping in the one-kidney one-clip Goldblatt hypertensive rat. J Clin Invest 1982; 69: 55-62.
30. Katholi RE, Whitlow PL, Hageman GR, et al. Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves in the dog. J Hypertens 1984; 2: 349-59.
31. Ye S, Gamburd M, Mozayeni P, et al. A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens 1998; 11: 723-8.
32. Ye S, Ozgur B and Campese VM. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int 1997; 51: 722-7.
33. Ye S, Zhong H, Yanamadala V, et al. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 2002; 15: 717-24.
34. Zucker IH. Novel mechanisms of sympathetic regulation in chronic heart failure. Hypertension 2006; 48: 1005-11.
35. DiBona GF. (2000a). Nervous kidney. Interaction between renal sympathetic nerves and the reninangiotensin system in the control of renal function. Hypertension 2000; 36: 1083-8.
36. DiBona GF. Peripheral and central interactions between the reninangiotensin system and the renal sympathetic nerves in control of renal function. Ann N Y Acad Sci 2001; 940: 395-406.
37. Miyajima E,Yamada Y, Yoshida Y, et al. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension 1991; 17: 1057-62.
38. DiBona GF. Central sympathoexcitatory actions of angiotensin II: role of type 1 angiotensin II receptors. J Am Soc Nephrol 1999; 10(Suppl. 11): 90-4.
39. Hendel MD, Collister JP. Renal denervation attenuates long-term hypertensive effects of angiotensin ii in the rat. Clin Exp Pharmacol Physiol 2006; 33: 1225-30.
40. Matsukawa T, Gotoh E, Minamisawa K, et al. Effects of intravenous infusions of angiotensin II on muscle sympathetic nerve activity in humans. Am J Physiol 1999; 261: 690-6.
41. Hendler NH and Livingston A. The localization over time of exogenous aldosterone and angiotensin II in various organs. Pavlov J Biol Sci 1978; 13: 187-93.
42. De Nicola AF, Tornello S, Weisenberg L, et al. Uptake and binding of [3H]aldosterone by the anterior pituitary and brain regions in adrenalectomized rats. Horm Metab Res 1981; 13: 103-6.
43. Birmingham MK, Sar M, Stumpf WE. Localization of aldosterone and corticosterone in the central nervous system, assessed by quantitative autoradiography. Neurochem Res 1984; 9: 333-50.
44. Funder J, Myles K. Exclusion of corticosterone from epithelial mineralocorticoid receptorsis insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology 1996; 137: 5264-68.
45. Uhr M, Holsboer F, Muller MB. Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1bP-glycoproteins. J Neuroendocrinol 2002; 14: 753-9.
46. Zhang ZH, Yu Y, Kang YM, et al. Aldosterone acts centrally to increase brain renin-angiotensin system activity and oxidative stress in normal rats. Am J Physiol Heart Circ Physiol 2008; 294: 1067-74.
47. Triposkiadis F, Karayannis G, Giamouzis G, et al. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 2009; 54: 1747-62.
48. Krukoff TL. Central actions of nitric oxide in regulation of autonomic functions. Brain Res Brain Res Rev 1999; 30: 52-65.
49. Tsioufis C, Aggelis A, Dimitriadis K, et al. Relationships of osteoprotegerin with albuminuria and asymmetric dimethylarginine in essential hypertension: integrating vascular dysfunction. Expert Opin Ther Targets 2011; 15 (12): 1347-53.
50. Mallamaci F, Tripepi G, Maas R, et al. Analysis of the relationship between norepinephrine and asymmetric dimethylarginine levels among patients with end-stage renal disease. J Am Soc Nephrol 2004; 15: 435-41.
51. Xu J, Li G, Wang P, et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest 2005; 115: 1275-80.
52. Desir GV. Renalase deficiency in chronic kidney disease, and its contribution to hypertension and cardiovascular disease. Curr Opin Nephrol Hypertens 2008; 17(2): 181-5.
53. Converse RL Jr, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327: 1912-8
54. Hausberg M, Kosch M, Harmelink P, et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106: 1974-9.
55. Schlaich M, Krum H, Walton T, et al. A novel catheter based approach to denervate the human kidney reduces blood pressure and muscle sympathetic nerve activity in a patient with end stage renal disease and hypertension. J Hypertension 2009; 27: 437.
56. Kim KE, Onesti G, Schwartz AB, et al. Hemodynamics of hypertension in chronic end-stage renal disease. Circulation 1972; 46: 456-64.
57. Brecht HM, Ernst W, Koch KM: Plasma noradrenaline levels in regular haemodialysis patients. Proc Eur Dial Transplant Assoc 1976; 12: 281-90.
58. Blankestijn PJ. Sympathetic hyperactivity - a hidden enemy in chronic kidney disease patients. Perit Dial Int 2007; 27: 293-7.
59. Grassi G, Quarti-Trevano F, Seravalle G, et al. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension 2011; 57: 846-51.
60. Klein IHHT, Ligtenberg G, Oey P L, et al. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001; 12: 2427-33.
61. Grassi G, Cattaneo BM, Seravalle G, et al. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 1998; 31: 68-72.
62. DiBona GF. Sympathetic nervous systemand the kidney in hypertension. Curr Opin Nephrol Hypertens 2002; 11: 197-200.
63. Neumann J, Ligtenberg G, Klein II, et al. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int 2004; 65: 1568-76.
64. Zoccali C, Mallamaci F, Parlongo S et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354-59.
65. Zoccali C, Mallamaci F, Tripepi G, et al. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 2002; 40: 41-6
66. Mancia G, Grassi G, Giannattasio C, et al. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999; 34: 724-8.
67. Tracey KJ: The inflammatory reflex. Nature 2002; 420: 853-9.
68. Aizawa T, Ishizaka N, Taguchi J, et al. Heme oxygenase-1 is upregulated in the kidney of angiotensin II-induced hypertensive rats: possible role in renoprotection. Hypertension 2000; 35: 800-6.
69. Erami C, Zhang H, Ho JG, et al. Alpha(1)-adrenoceptor stimulation directly induces growth of vascular wall in vivo. Am J Physiol Heart Circ Physiol 2002; 283: 1577-87.
70. Johnson RJ, Gordon KL, Suga S, et al. Renal injury and saltsensitive hypertension after exposure to catecholamines. Hypertension 1999; 34: 151-9.
71. Zhang H, Faber JE. Trophic effect of norepinephrine on arterial intima-media and adventitia is augmented by injury and mediated by different alpha1-adrenoceptor subtypes. Circ Res 2001; 89: 815-22.
72. Burnstock G. Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol 2002; 22: 364-73.
73. Inscho EW. P2 receptors in regulation of renal microvascular function. Am J Physiol Renal Physiol 2001; 280: 927-44.
74. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 2003; 83: 253-307.
75. Schwiebert EM, Kishore BK. Extracellular nucleotide signaling along the renal epithelium. Am J Physiol Renal Physiol 2001; 280: 945-63.
76. Greenwood JP, Scott EM, Stoker JB, et al. Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. J Am Coll Cardiol 2001; 38: 1711-17.
77. Kelm M, Schafer S, Mingers S, et al. Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients. J Hypertens 1996; 14: 1357-64.
78. Tsioufis C, Kokkinos P, Macmanus C, et al. Left ventricular hypertrophy as a determinant of renal outcome in patients with high cardiovascular risk. J Hypertens 2010; 28(11): 2299-308.
79. Rump LC, Amann K, Orth S, et al. Sympathetic overactivity in renal disease: a window to understand progression and cardiovascular complications of uraemia? Nephrol Dial Transplant 2000; 15: 1735-48.
80. Amann K, Rump LC, Simonaviciene A, et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 2000; 11: 1469-78.
81. Amann K, Koch A, Hofstetter J, et al. Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha and beta blockers. Kidney Int 2001; 60: 1309-23.
82. Barone FC, Nelson AH, Ohlstein EH, et al. Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats. J Pharmacol Erxp The 1996; 279: 948-55.
83. Wong VY, Laping NJ, Nelson AH, et al. Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expression. Br J Pharmacol 2001; 134: 977-84.
84. Griffin KA, Abu-Amarah I, Picken M, et al. Renoprotection by ACE inhibition or aldosterone blockade is blood pressuredependent. Hypertension 2003; 41: 201-6.
85. Bidani AK, Griffin KA, Bakris G, et al. Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int 2000; 57: 1651-61.
86. Vonend O, Marsalek P, Russ H, et al. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 2003; 21: 1709-17.
87. Cohn JN, Pfeffer MA, Rouleau J et al: Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003; 5: 659-67.
88. Strojek K, Grzeszczak W, Gorska J, et al. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol 2001; 12: 602-5.
89. Neumann J, Ligtenberg G, Oey L et al: Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol 2004; 15: 2902-7.
90. Klein IH, Ligtenberg G, Oey PL, et al. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003; 14: 425-30.
91. Neumann J, Ligtenberg G, Klein IH, et al. Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment. Hypertension 2007; 49: 506-10.
92. Siddiqi L, Oey PL, Blankestijn PJ. Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients Nephrol Dial Transplant. 2011; 26: 2930-4.
93. Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340: 1321-8.
94. Siddiqi L, Prakken NH, Velthuis BK, et al. Sympathetic activity in chronic kidney disease patients is related to left ventricular mass despite antihypertensive treatment Nephrol Dial Transplant 2010; 25: 3272-7.
95. Penne EL, Neumann J, Klein IH, et al. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment. J Nephrol 2009; 22: 208-15.
96. Peet M.M. Hypertension and its surgical treatment by bilateral supradiaphragmatic splanchnicectomy. Am J Surg 1948; 75: 48-68.
97. Keith NM, Wagener HP, Barker NW. Some different types of essential hypertension: their course and prognosis. Am J Med Sci 1974; 286: 336-45.
98. Smithwick RH. Surgical treatment of hypertension. Am J Med 1948; 4: 744-59.
99. Isberg EM, Peet MM. The influence of supradiaphragmatic splanchnicectomy on the heart in hypertension. Am Heart J 1948; 35: 567-83
100. Allen EV. Sympathectomy for essential hypertension. Circulation 1952; 6: 131-40.
101. Smithwick RH. Hypertensive vascular disease: results of and indications for splanchnicectomy. J Chron Dis 1955; 1: 477-96.
102. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-81.
103. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA 1967; 202: 1028-34.
104. Schlaich MP, Sobotka PA, Krum H, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361: 932-34.
105. DiBona GF and Sawin LL. Effect of renal denervation on dynamic autoregulation of renal blood flow. Am J Physiol Renal Physiol 2004; 286: 1209-18.
106. Nagasu H, Satoh M, Kuwabara A, et al. Renal denervation reduces glomerular injury by suppressing NAD(P)H oxidase activity in Dahl salt-sensitive rats. Nephrol Dial Transplant 2010; 25: 2889-98.
107. Veelken R, Vogel EM, Hilgers K, et al. Autonomic renal denervation ameliorates experimental glomerulonephritis. J Am Soc Nephrol 2008; 19: 1371-8.
108. Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-9.
109. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911-7.
110. Katholi RE, Rocha-Singh KJ, Goswami NJ, et al. Renal nerves in the maintenance of hypertension: a potential therapeutic target. Curr Hypertens Rep 2010; 12: 196-204.
111. Lazarus JM, Bourgoignie JJ, Buckalew VM, et al. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension 1997; 29: 641-50.
112. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754-62.
113. Hering D, Mahfoud F, Walton AS, et al. Renal Denervation in Moderate to Severe CKD. JASN 2012; 23: 1250-7.
114. Liu FY and Cogan MG. Angiotensin II stimulation of hydrogen ion secretion in the rat early proximal tubule. Modes of action, mechanism and kinetics. J Clin Invest 1988; 82: 601-7.